1. Di Bonito M, Cantile M, Collina F, Scognamiglio G, Cerrone M, La Mantia E, et al. Overexpression of cell cycle progression inhibitor geminin is associated with tumor stem-like phenotype of triple-negative breast cancer. J Breast Cancer. 2012. 15:162–171.
Article
2. Yamazaki M, Fujii S, Murata Y, Hayashi R, Ochiai A. High expression level of geminin predicts a poor clinical outcome in salivary gland carcinomas. Histopathology. 2010. 56:883–892.
Article
3. Tamura T, Shomori K, Haruki T, Nosaka K, Hamamoto Y, Shiomi T, et al. Minichromosome maintenance-7 and geminin are reliable prognostic markers in patients with oral squamous cell carcinoma: immunohistochemical study. J Oral Pathol Med. 2010. 39:328–334.
Article
4. Shomori K, Nishihara K, Tamura T, Tatebe S, Horie Y, Nosaka K, et al. Geminin, Ki67, and minichromosome maintenance 2 in gastric hyperplastic polyps, adenomas, and intestinal-type carcinomas: pathobiological significance. Gastric Cancer. 2010. 13:177–185.
Article
5. Nishihara K, Shomori K, Tamura T, Fujioka S, Ogawa T, Ito H. Immunohistochemical expression of geminin in colorectal cancer: implication of prognostic significance. Oncol Rep. 2009. 21:1189–1195.
Article
6. Blanchard Z, Malik R, Mullins N, Maric C, Luk H, Horio D, et al. Geminin overexpression induces mammary tumors via suppressing cytokinesis. Oncotarget. 2011. 2:1011–1027.
Article
7. Gonzalez MA, Tachibana KE, Chin SF, Callagy G, Madine MA, Vowler SL, et al. Geminin predicts adverse clinical outcome in breast cancer by reflecting cell-cycle progression. J Pathol. 2004. 204:121–130.
Article
8. Martin CM, Astbury K, McEvoy L, O'Toole S, Sheils O, O'Leary JJ. Gene expression profiling in cervical cancer: identification of novel markers for disease diagnosis and therapy. Methods Mol Biol. 2009. 511:333–359.
Article
9. Shrestha P, Saito T, Hama S, Arifin MT, Kajiwara Y, Yamasaki F, et al. Geminin: a good prognostic factor in high-grade astrocytic brain tumors. Cancer. 2007. 109:949–956.
Article